Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 5/20 | 0.51 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP4Z1 | Q86W10 | 2/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7267292 | 0.98 | SLC9A1 (0.53) | SLC9A1TLR8TP53MAPTSMN1; SMN2 | |
| SCHEMBL28327270 | 0.98 | SLC9A1 (0.53) | SLC9A1TLR8TP53MAPTSMN1; SMN2 | |
| SCHEMBL5983792 | 0.98 | SLC9A1 (0.53) | SLC9A1TLR8TP53MAPTSMN1; SMN2 | |
| SCHEMBL5981819 | 0.95 | SLC9A1 (0.50) | SLC9A1TLR8TP53MAPTSMN1; SMN2 | |
| SCHEMBL1828029 | 0.88 | SLC9A1 (0.47) | SLC9A1TLR8TP53MAPTSMN1; SMN2 | |
| SCHEMBL27974615 | 0.83 | SLC9A1 (0.44) | SLC9A1TLR8TP53MAPTSMN1; SMN2 | |
| SCHEMBL27806619 | 0.83 | SLC9A1 (0.45) | SLC9A1TLR8TP53MAPTSMN1; SMN2 | |
| SCHEMBL28034903 | 0.83 | HPGD (0.40) | MAPTSMN1; SMN2ALDH1A1HTTMPO | |
| SCHEMBL357229 | 0.81 | TSHR (0.37) | SMN1; SMN2TDP1ALDH1A1MPO | |
| SCHEMBL27784620 | 0.81 | SLC9A1 (0.50) | SLC9A1TLR8TP53SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6316482-B1 | FOR THERAPY AND PROPHYLAXIS OF HYPERTENSION, HEART FAILURE, RENAL INSUFFICIENCY, EDEMA, ASCITES, VASOPRESSIN PARASECRETION SYNDROME, HEPATOCIRRHOSIS, HYPONATREMIA, HYPOKALEMIA, DIABETIC, CIRCULATION DISORDER, CEREBROVASCULAR DISEASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-13 | — | — | US | claimed |
| EP-0278908-A2 | Heterocyclic compounds | Zyma SA (CH) | 1988-08-17 | — | — | EP | claimed |
| JP-2007157899-A | ORGANIC ELECTROLUMINESCENCE ELEMENT | TOYO INK MFG CO LTD | 2007-06-21 | — | — | JP | disclosed |
| EP-1634888-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1600452-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1600451-A2 | Synthesis of 2'-deoxy-l-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | PHARMASSET, INC. | 2005-04-28 | — | — | US | disclosed |
| EP-1232166-A2 | SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES | Pharmasset Limited (US) | 2002-08-21 | — | — | EP | disclosed |
| US-6316482-B1 | FOR THERAPY AND PROPHYLAXIS OF HYPERTENSION, HEART FAILURE, RENAL INSUFFICIENCY, EDEMA, ASCITES, VASOPRESSIN PARASECRETION SYNDROME, HEPATOCIRRHOSIS, HYPONATREMIA, HYPOKALEMIA, DIABETIC, CIRCULATION DISORDER, CEREBROVASCULAR DISEASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-13 | — | — | US | disclosed |
| WO-2001034618-A2 | SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES | PHARMASSET LIMITED (US) | 2001-05-17 | — | — | WO | disclosed |
| US-6207693-B1 | Benzamide derivatives having a vasopressin antagonistic activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| CN-1083812-A | Benzimidazoles contains the pharmaceutical composition of these compounds and their preparation | KRAL THOMAE GMBH (DE) | 1994-03-16 | — | — | CN | disclosed |
| EP-0581166-A1 | Benzimidazoles, process for their preparation and their use as angiotensin-II antagonists | Dr. Karl Thomae GmbH (DE) | 1994-02-02 | — | — | EP | disclosed |
| EP-0560330-A2 | Substituted benzimidazolyl derivatives, therapeutic agents containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-09-15 | — | — | EP | disclosed |
| EP-0556789-A2 | Substituted biphenyl derivatives, therapeutic agents containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-08-25 | — | — | EP | disclosed |
| EP-0502314-A1 | Benzimidazol, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-09-09 | — | — | EP | disclosed |
| EP-0468470-A1 | Benzimidazoles, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-01-29 | — | — | EP | disclosed |
| US-4904675-A | Phamacologically active 5-carboxy-2-(5-tetrazolyl) pyridines | ZYMA SA (CH) | 1990-02-27 | — | — | US | disclosed |
| EP-0278908-A3 | HETEROCYCLIC COMPOUNDS | Zyma SA (CH) | 1990-01-17 | — | — | EP | disclosed |
| EP-0278908-A2 | Heterocyclic compounds | Zyma SA (CH) | 1988-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | CCNH, ADAR, NSUN2 | SLC9A1 3264/4885TLR8 4139/4885TP53 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.